GSK says its drug for chron­ic hep B could ‘lead to a func­tion­al cure’ — but will it be alone or in com­bi­na­tion?

GSK, new­ly brand­ed and soon-to-be de­merged, shared in­ter­im re­sults from its Phase II tri­al on its chron­ic he­pati­tis B treat­ment, one that it says has the “po­ten­tial to lead to a func­tion­al cure.”

At a pre­sen­ta­tion at the EASL In­ter­na­tion­al Liv­er Con­gress, GSK shared that in around 450 pa­tients who re­ceived its hep B drug bepirovirsen for 24 weeks, just un­der 30% had he­pati­tis B sur­face anti­gen and vi­ral DNA lev­els that were too low to de­tect.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.